A recent study compared the effects of multiple adjuvant chemoradiotherapy regimens on overall survival in patients with gastric or gastroesophageal junction adenocarcinoma. READ MORE
High expression of a specific protein is associated with an improved 5-year survival rate of almost 28% in gastric cancer.
Recent research compared the efficacy of chemotherapy vs best supportive care, combination vs single-agent chemotherapy, and multiple different chemotherapy combinations in advanced gastric cancer.
Post-treatment/preoperative tumor response, as measured on PET, does not predict outcomes in patients with gastric and gastroesophageal junction adenocarcinoma.
Analysis of multiple data sets has helped to elucidate how four recently revealed molecular subsets of gastric cancer might best be managed.
Research in Review
Few patients with metastatic urothelial carcinoma of the bladder are surviving as long in the real-world as those in clinical trials, according to new research.
Administering capecitabine after surgery extends survival by a median of 17 months compared with surgery alone for patients with biliary tract cancer, according to research that will be presented at the 2017 ASCO Annual Meeting.
Recommended primary treatment for non-muscle invasive micropapillary urothelial carcinoma is often foregone in community cancer centers and academic centers.
Adding cetuximab to chemoradiation for squamous cell carcinoma of the anal canal is associated with lower incidence of locoregional failure but high toxicity, according to the results of a study published in the Journal of Clinical Oncology (March 2017;35:718-726).